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AbstrACt
Introduction Poorly differentiated (PD), extrapulmonary 
(EP), neuroendocrine carcinomas (NECs) are rare but 
aggressive neuroendocrine neoplasms. First- line treatment 
for advanced disease is an etoposide and platinum- based 
chemotherapy combination. There is no established 
second- line treatment for patients with PD- EP- NEC, and 
this is an area of unmet need.
Methods and analysis NET-02 is a UK, multicentre, 
randomised (1:1), parallel group, open- label, phase 
II, single- stage selection trial of liposomal irinotecan 
(nal- IRI)/5- fluorouracil (5- FU)/folinic acid or docetaxel 
as second- line therapy in patients with progressive 
PD- EP- NEC. One hundred and two eligible participants 
will be randomised to receive either nal- IRI/5- FU/folinic 
acid or docetaxel. The primary objective is to determine 
the 6- month progression- free survival (PFS) rate. The 
secondary objectives of this study are to determine PFS, 
overall survival, objective response rate, toxicity, quality 
of life and whether neuron- specific enolase is predictive 
of treatment response. If either treatment is found to have 
a 6- month PFS rate of at least 25%, that treatment will 
be considered for a phase III trial. If both treatments meet 
this target, prespecified selection criteria will be applied to 
establish which treatment to take forward.
Ethics and dissemination This study has ethical 
approval from the Greater Manchester Central Research 
Ethics Committee (reference no. 18/NW/0031) and clinical 
trial authorisation from the Medicine and Healthcare 
Products Regulatory Agency. Results will be published 
in peer- reviewed journals and uploaded to the European 
Union Clinical Trials Register.
trial registration numbers ISRCTN10996604, 
NCT03837977, EudraCT Number: 2017-002453-11
IntroduCtIon
neuroendocrine carcinomas
Neuroendocrine carcinomas (NECs) are a 
rare, high- grade, poorly differentiated (PD) 
form of neuroendocrine neoplasms (NENs).1 
The annual incidence of PD extrapulmonary 
(EP) NEC is approximately one diagnosis per 
100 000 persons.2 3 These tumours are char-
acterised by aggressive histological features; 
high Ki-67 index (>20% by definition, but 
usually higher (>75%)),4 extensive necrosis 
strengths and limitations of this study
 ► The trial is designed to ensure, with a high probabil-
ity, that the most efficacious treatment is selected to 
be taken forward to a phase III trial.
 ► Prospectively defined decision criteria in this trial 
will enable earlier planning of a phase III trial if these 
targets are reached.
 ► The trial is not powered to directly compare the two 
treatment arms in this study.
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and nuclear atypia, and are classified as NEC grade 3 
according to WHO 2010 classification.5
First- line treatment for PD- EP- NECs has remained 
largely unchanged since a study in the early 1990s 
reported antitumour activity and high tumour response 
rates (RRs) produced by an etoposide–platinum combi-
nation.6 Nevertheless, disease progression invariably 
occurs in patients during or following completion of first- 
line therapy, and a standard second- line treatment is yet 
to be determined.
Current second-line treatment options for patients with a nEC 
diagnosis
For patients with advanced PD- EP- NEC, combination 
regimens such as irinotecan, 5- fluorouracil (5- FU) and 
folinic acid are a second- line treatment option currently 
used, without robust trial evidence.7 This combination 
has been recommended for patients with a NEC diagnosis 
with a Ki-67 ≥55%, whereas some literature recommends 
temozolomide- based combinations for those with a Ki-67 
<55%.8 9 In devising treatment strategies for PD- EP- NEC, 
many refer to the extensive literature on high- grade NEC 
of the lung, for which docetaxel is a second- line therapy 
option.9
Several small retrospective studies have published 
results for the outcomes of second- line chemotherapy 
after failure of the etoposide–platinum combination in 
patients with grade 3 NECs.7–13 The NORDIC- NEC study 
reported predictive and prognostic factors for treatment 
and survival in 305 patients with advanced gastrointes-
tinal NEC.9 Second- line chemotherapy was administered 
to 100 patients; of these, 35 received temozolomide- based 
chemotherapy and 20 received docetaxel- based chemo-
therapy. Of 84 evaluable patients, the RR was 18%. Those 
whose tumours had a Ki-67 <55% had a lower RR, but 
better survival than patients whose tumours had a Ki-67 
≥55%. The median overall survival (OS) for patients 
treated with first- line platinum- based chemotherapy in 
the advanced setting is 11–16.4 months.9 14 In a system-
atic review and meta- analysis of second- line treatment in 
595 patients with advanced PD- EP- NEC, the median RR 
was 18%, the median progression- free survival (PFS) was 
2.5 months (range 1.2–6.0) and the median OS was 7.6 
months (range 3.2–22).15
Liposomal irinotecan
Irinotecan, a topoisomerase I inhibitor, works to arrest 
uncontrolled cell growth by preventing the unwinding of 
DNA, therefore, preventing cell replication and tumour 
growth.16
Liposomal irinotecan (nal- IRI) (ONIVYDE, Servier) 
is irinotecan encapsulated in a liposome drug delivery 
system. This stable liposome formulation of irinotecan 
has several attributes that may provide an improved thera-
peutic index; controlled and sustained release, high intra-
vascular drug retention and enhanced permeability.16 17 
The improved pharmacokinetics and biodistribution of 
nal- IRI in comparison to irinotecan may have clinical 
benefit in patients with NEC.
Pharmacokinetic studies have demonstrated that once 
irinotecan is released from the liposomes, the conver-
sion to the active metabolite, SN-38, is similar to that of 
unencapsulated irinotecan.16 18 Thus, nal- IRI and unen-
capsulated irinotecan have demonstrated similar adverse 
reactions (ARs) in patients, the most common of which 
include gastrointestinal events and myelosuppression.16 18
rationale for the use of nal-IrI in combination with 5-Fu and 
folinic acid
Preclinical evidence supports the hypothesis that nal- IRI 
modifies the tumour microenvironment in a manner that 
should make tumours more susceptible to 5- FU/folinic 
acid, through decreasing tumour hypoxia and increasing 
small molecule perfusion.19 20
Given the relative absence of overlapping toxic 
effects among nal- IRI, 5- FU and folinic acid, a regimen 
combining these agents was studied in a phase I, dose- 
escalation trial of solid tumours.21 Among the 15 efficacy- 
evaluable participants, the overall disease control rate 
was 73.3%. Among the six participants who received the 
nal- IRI maximum tolerated dose of 80 mg/m2, the objec-
tive RR (ORR) and disease control rate were 16.7% and 
83.3%, respectively.
In the NAPOLI-1 phase III trial of nal- IRI, with or 
without 5- FU and folinic acid, versus 5- FU and folinic 
acid alone, in the treatment of patients with meta-
static pancreatic ductal adenocarcinoma after receiving 
gemcitabine- based therapy, an increase in OS for those 
treated with a combination of nal- IRI and 5- FU/folinic 
acid was reported compared with those treated with 5- FU 
and folinic acid alone (HR for survival 0.67, 95% CI 0.49 
to 0.92).22
rationale for the use of docetaxel
The National Comprehensive Cancer Network Clinical 
Practice Guidelines in Oncology, for the treatment of small 
cell and non- small cell lung cancer, include docetaxel 
as a second- line treatment option in patients who have 
progressed on primary etoposide–platinum combination 
therapy.23 24 Based on observed RRs, survival, quality of 
life (QoL) and toxicities, the optimal dose of docetaxel 
in pretreated patients with non- small cell lung cancer is 
75 mg/m2 every 3 weeks.25
study rationale and AIM
Treatment of patients with advanced PD- EP- NEC, to date, 
has been analogous to that of high- grade NEC (small cell 
or non- small cell cancer) of the lung.6 The standard arm 
of NET-02 is that used in high- grade lung NEC, of which 
docetaxel is a second- line therapy option,23 and combina-
tion regimens such as irinotecan/5- FU are a second- line 
therapy option currently used, without trial evidence, for 
this subset of patients.7 Prospective collaborative trials, 
with translational endpoints, are warranted and may 
inform future biomarker- driven studies.
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Therefore, the overall aim of this trial is to assess the 
efficacy of nal- IRI/5- FU/folinic acid or docetaxel, sepa-
rately, as second- line therapy in patients with progressive 
PD- EP- NEC, with selection criteria applied to establish 
which treatment to take forward into a phase III trial.
MEthods And AnALysIs
trial objectives
The primary objective of the trial is to determine the 
6- month PFS rate, defined as a binary outcome (progres-
sion free or not) within the time frame of treatment start 
date until 6 months postrandomisation.
The secondary objectives of the trial are to determine:
 ► PFS (defined as the time from randomisation to 
progression or death from any cause).
 ► OS (defined as the time from randomisation to death 
from any cause).
 ► ORR at 6 months postrandomisation (defined using 
the Response Evaluation Criteria in Solid Tumours 
V.1.1 measurements).26
 ► Toxicity as per Common Terminology Criteria for 
Adverse Events (CTCAE) V.5.0.
 ► QoL (defined using European Organisation for 
Research and Treatment of Cancer (EORTC) QoL 
validated questionnaires (QLQ) C30 (EORTC QLQ- 
C30)27 and GINET21 (EORTC QLQ- GINET21)).27 28
 ► Association between neuron- specific enolase concen-
tration and treatment response.
Additional exploratory objectives, analysing participant 
samples, will include:
 ► Quantification of circulating tumour cells (CTCs) and 
circulating tumour DNA at baseline, 6 weeks and on 
progression, to identify any correlation with disease- 
related outcomes.
 ► Molecular profiling of CTCs, circulating tumour DNA 
and tumour tissue (further immunohistochemistry on 
tumour tissue may also be required) to identify any 
correlation with disease- related outcomes.
 ► Generation of mouse models of PD- EP- NEC.
trial design
The NET-02 trial is a UK, multicentre, randomised (1:1), 
parallel group, open- label, phase II, single- stage selection 
trial of nal- IRI/5- FU/folinic acid or docetaxel as second- 
line therapy in patients with progressive PD- EP- NEC.
The design is an adaptation of a one- stage trial design 
proposed by Simon et al, where the A’Hern design is first 
implemented to assess efficacy of each treatment sepa-
rately, to ensure a prespecified minimum level of activity 
prior to selection.29 Should both treatments be suffi-
ciently efficacious, prespecified selection criteria are then 
applied to establish which treatment to take forward into 
a phase III trial. The intention of the trial is to show that 
the regimens are sufficiently active in this patient popu-
lation, but not to show that one regimen is significantly 
superior to the other.
The A’Hern method is advantageous over other single- 
stage designs, since it uses the exact binomial distribution, 
as opposed to a normal approximation to the binomial 
distribution which can lead to substantial error in small 
trials.30 Additionally, prospectively defined decision criteria, 
specified below, are applied, which if reached, could enable 
earlier planning for a phase III follow- on trial.
Participants will be randomised to receive either nal- 
IRI/5- FU/folinic acid, administered every 14 days or 
docetaxel, administered every 21 days. Trial treatment will 
continue until progressive disease, intolerable toxicity, 
delay of treatment for more than 28 days, development of 
any condition or occurrence of any event, which, in the 
opinion of the local investigator, justifies discontinuation 
of treatment, participant request or until 6 months after 
the last participant is randomised, whichever occurs first. 
Figure 1 displays the full trial schema.
trial population and sample size
The NET-02 trial will recruit patients diagnosed with 
PD- EP- NEC (Ki-67 >20% and grade 3, confirmed by 
histology). Patients will be eligible for the trial if they 
meet all of the inclusion criteria and do not satisfy any of 
the exclusion criteria listed in table 1.
One hundred and two eligible participants will be 
randomised to receive either nal- IRI/5- FU/folinic acid 
or docetaxel. Allowing for a 5% drop- out rate, this will 
provide 80% power for demonstrating that the one- sided 
95% CI for the 6- month PFS rate excludes 15%, if the true 
rate is at least 30%, where 30% is the required level of 
efficacy and a rate of 15% or less would give grounds for 
rejection, that is, the relevant treatment would be consid-
ered not to have reached an acceptable level of efficacy 
to warrant further evaluation. The proportions of 15% 
and 30% were chosen in line with existing literature; of 
those who reported the proportion progression free at 
6 months, the lowest was approximately 15%11 and the 
highest approximately 25%.7 Therefore, for either trial 
treatment to be taken forward for further research, they 
should provide estimates that are at least as good as the 
lower value and aim to improve on the higher value.
A treatment arm may be considered for further evalua-
tion using the treatment selection process described below, 
if at least 12 out of 48 evaluable participants are progression 
free at 6 months (equating to a success rate of 25%, with a 
lower one- sided 95% confidence limit of 15.1%).
treatment selection
If both treatments successfully exceed the predefined 
criteria, having lower one- sided 95% confidence limits 
greater than 15%, Simon et al’s design proposes that the 
treatment with the higher PFS rate at 6 months should be 
selected, regardless how small its advantage over the other 
treatment appears.29 Nevertheless, to ensure that the 
more efficacious treatment is selected with a high prob-
ability, if the difference in the 6- month PFS rates is less 
than 5%, additional selection criteria, including toxicity 
rates and QoL score, will be considered. If only one of the 
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Figure 1 Trial schema. ECOG, Eastern Co- operative Oncology Group; EP, extrapulmonary; EORTC, European Organisation 
for Research and Treatment of Cancer; 5- FU, 5- fluorouracil; NEC, neuroendocrine carcinoma; nal- IRI, liposomal irinotecan; PD, 
poorly differentiated.
treatments successfully exceeds the predefined criteria, 
this treatment will be selected for further investigation.
recruitment, registration and randomisation
Participants will be recruited from 16 UK sites (see online 
supplementary material) over a 37- month period. Poten-
tial participants will be approached, regarding trial partic-
ipation, during the standard clinic visit at which their 
progression following first- line chemotherapy is discussed 
and will be provided with a verbal and written explana-
tion of the trial. Patients, who provide written informed 
consent, to the site principal investigator or delegate, will 
be registered onto the trial. Consent to the use of blood 
samples for future projects and mouse model generation 
(The Christie National Health Service (NHS) Founda-
tion Trust participants only) is optional.
Recruitment of participants to the NET-02 trial requires 
trial- specific investigations to confirm eligibility. Conse-
quently, recruitment is a two- step process involving regis-
tration and randomisation.
Initial registration will involve all patients who have 
provided written informed consent. Patients will undergo 
investigations to confirm eligibility including a full blood 
count, biochemistry and renal function assessment, an ECG 
and a pregnancy test (if applicable) to confirm that they 
satisfy the eligibility criteria specified in table 1.
Once all other screening investigations are success-
fully completed and prior to meeting with the clinician 
and randomisation, two baseline QoL questionnaires 
(EORTC QLQ- C3027 and EORTC QLQ- GINET2128 will be 
completed.
Patients identified as eligible, following the eligibility 
assessments, will be randomised. If more than 14 days 
have elapsed since the initial eligibility blood tests, these 
must be repeated prior to randomisation, to ensure that 
the patient remains eligible. Registration and randomis-
ation will be performed centrally using either the Leeds 
Clinical Trials Research Unit (CTRU) automated tele-
phone or web- based system.
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Table 1 NET-02 inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Age≥18 years and life expectancy >3 months.
2. Diagnosed with poorly differentiated (as defined by WHO 
in 2010, Ki-67 >20%) EP- NEC (grade 3, confirmed by 
histology). Carcinoma of unknown primary is allowed if 
lung primary has been excluded following review by the 
multidisciplinary team.
3. Prior treatment with first- line platinum- based 
chemotherapy for NEC in the advanced setting and ≥28 
days from day 1 of the previous treatment cycle.
4. Documented radiological evidence of disease progression 
OR discontinuation of first- line platinum- based 
chemotherapy due to intolerance.
5. Measurable disease according to RECIST V.1.1.
6. Eastern Co- operative Oncology Group performance status 
≤2.
7. Adequate renal function with serum creatinine ≤1.5 times 
upper limit of normal (ULN) and creatinine clearance 
≥30 mL/min according to Cockroft- Gault or Wright formula. 
If the calculated creatinine clearance is <30 mL/min, 
glomerular filtration rate (GFR) may be assessed using 
either Cr51- EDTA or 99mTc- DTPA clearance method to 
confirm if GFR is ≥30 mL/min).
8. Adequate haematological function: Hb ≥90 g/L, 
WCC≥3.0×109/L, ANC≥1.5×109/L, platelet count 
≥100×109/L.
9. Adequate liver function: serum total bilirubin ≤1.5 x ULN 
(biliary drainage is allowed for biliary obstruction) and ALT 
and/or AST≤2.5 x ULN in the absence of liver metastases, 
or ≤5 x ULN in the presence of liver metastases.
10. A negative pregnancy test is required at registration in 
women of childbearing potential.
11. Men and women of reproductive potential must agree 
to use a highly effective form of contraception during 
the study and for 6 months following the last dose of 
trial treatment. In addition, male participants should use 
a condom during study participation and for 6 months 
following the last dose of trial treatment.
12. Patients must be able to provide written informed consent.
13. Patients must be able and willing to comply with the terms 
of the protocol.
1. Known or suspected allergy or hypersensitivity reaction to any of the 
components of study treatment or their excipients.
2. Use (including self- medication) within 1 week of randomisation and 
for the duration of the study of any of the following: St. John’s wort, 
grapefruit, Seville oranges, medicines known to inhibit UGT1A1 (eg, 
atazanavir, gemfibrozil, indinavir) and medicines known to inhibit or 
induce either CYP3A4 or CYP3A5.
3. Previous treatment (for NEC) with any of the components of combination 
chemotherapy regimens detailed in this study (nal- IRI, 5- FU, irinotecan, 
topoisomerase inhibitors or taxane- based therapy).
4. Incomplete recovery from previous therapy in the opinion of the 
investigator (surgery/adjuvant therapy/radiotherapy/chemotherapy in 
advanced setting), including ongoing peripheral neuropathy of >Common 
Terminology Criteria for Adverse Events (CTCAE) V.5.0 grade 2 from 
previous platinum- based therapy.
5. Concurrent palliative radiotherapy involving target lesions used for this 
study (<28 days from discontinuation of radiotherapy). Radiotherapy for 
non- target lesions is allowed if other target lesions are available outside 
the involved field.
6. Patients must not have a history of other malignant diseases (within the 
previous 3 years, and there must be no evidence of recurrence), other 
than:
 – EP- NEC.
 – Non- melanoma skin cancer where treatment consisted of resection 
only or radiotherapy.
 – Ductal carcinoma in situ where treatment consisted of resection only.
 – Cervical carcinoma in situ where treatment consisted of resection only.
 – Superficial bladder carcinoma where treatment consisted of resection 
only.
7. Documented brain metastases, unless adequately treated (surgery or 
radiotherapy only), with no evidence of progression and neurologically 
stable off anticonvulsants and steroids.
8. Clinically significant gastrointestinal disorder (in the opinion of the 
treating clinician), including hepatic disorders, bleeding, inflammation, 
obstruction or diarrhoea >CTCAE grade 1 (at time of study entry).
9. Severe arterial thromboembolic events (myocardial infarction, unstable 
angina pectoris, stroke) less than 6 months before inclusion.
10. New York Heart Association class III or IV congestive heart failure, 
ventricular arrhythmias or uncontrolled blood pressure.
11. Severe bone marrow failure or bone marrow depression after 
radiotherapy or treatment with other antineoplastic agents (defined 
as haematological values of Hb or white blood cells or neutrophils or 
platelets not meeting inclusion criteria).
12. Known active hepatitis B virus, hepatitis C virus or HIV infection.
13. Active chronic inflammatory bowel disease.
14. Breastfeeding women.
15. Evidence of severe or uncontrolled systemic diseases, which, in the view 
of the treating clinician, makes it undesirable for the patient to participate 
in the trial.
16. Evidence of significant clinical disorder or laboratory finding which, in the 
opinion of the treating clinician, makes it undesirable for the patient to 
participate in the trial.
17. Medical or psychiatric conditions that impair the ability to give informed 
consent.
18. Any other serious uncontrolled medical conditions (in the opinion of the 
treating clinician).
ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; EDTA, ethylenediaminetetraacetic acid; EP, 
extrapulmonary; 5- FU, 5- fluorouracil; Hb, haemoglobin; nal- IRI, liposomal irinotecan; NEC, neuroendocrine carcinoma; RECIST, Response Evaluation 
Criteria in Solid Tumours; UGT, uridine diphosphate- glucuronosyl transferase; WCC, white cell count.
A minimisation programme, which incorporates a 
random element, will be used for randomisation to ensure 
treatment groups are well balanced for the following 
characteristics:
 ► Hospital site.
 ► Ki-67 marker (<55%, ≥55%).
 ► Eastern Co- operative Oncology Group (ECOG) 
performance status (0/1, 2).
 ► Presence of liver metastases (yes, no).
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 ► Response to first- line platinum- based chemotherapy 
(resistant disease (progression ≤6 months from 
completion of platinum- based therapy), sensitive 
disease (progression >6 months from completion of 
platinum- based therapy), platinum intolerant).
Following randomisation, baseline assessments will be 
conducted. These will include; medical history, demo-
graphics, baseline symptoms, physical examination, vital 
signs, CT scan (or MRI scan, if appropriate) of the thorax- 
abdomen- pelvis and staging within 28 days of starting 
trial treatment, one 10 mL blood sample for local meas-
urement of neuron- specific enolase and two 10 mL blood 
samples for central translational research. Confirmation 
of availability of archival paraffin- embedded tissue for 
translational research will also be sought. An additional 
10 mL blood sample may be taken for mouse model devel-
opment for consenting participants from The Christie 
NHS Foundation Trust.
Interventions
Nal- IRI (ONIVYDE, Servier), folinic acid and 5- FU will 
be administered sequentially. The recommended dose 
and regimen of nal- IRI is 80 mg/m2 body surface area 
(BSA) intravenously over 90 min (±10 min), followed by 
folinic acid as per local standard practice (recommended 
dose is 350 mg fixed dose), followed by 5- FU 2400 mg/
m2 BSA intravenously over 46 hours. Following cycle 1, 
subsequent doses will be administered every 14 days (+3 
days/−1 day). Where it is not possible to administer nal- 
IRI due to toxicity, 5- FU/folinic acid can be administered 
as a monotherapy.
Docetaxel will be administered at a dose of 75 mg/m2 
BSA as an intravenous infusion over 60 min, or as per 
local standard practice. Following cycle 1, subsequent 
doses will be administered every 21 days (+3 days/−1 day).
Dosing may be postponed for up to 28 days from when 
it was due, to allow for (but not limited to) recovery from 
treatment- related toxicities, infection or following patient 
request. In the event of a delay due to toxicity, a dose 
modification (see online supplementary material) may 
be required at subsequent cycles following a dose delay. 
If a patient’s dose is reduced due to toxicity, it will remain 
reduced for the duration of treatment. Patients who have 
already received two dose reductions and experience addi-
tional toxicities that would require further dose reduc-
tion should discontinue study medication. However, in 
the event that the participant is deriving clinical benefit 
and the treating clinician would prefer to continue treat-
ment, an additional dose reduction may be permitted at 
the discretion of the chief investigator or delegate. If the 
toxicity recovery duration (to ≤grade 2 CTCAE V.5.0 or 
baseline) is more than 28 days, the participant should 
discontinue trial treatment. Participants who have prema-
turely discontinued treatment will continue to attend 
8- weekly clinic visits for CT scans and have follow- up data 
collected, unless the participant withdraws consent for 
follow- up visits and further data collection.
All concurrent medical conditions and complications 
of the underlying malignancy will be treated at the discre-
tion of the treating physician according to local standards 
of medical care. Participants can receive analgesics, anti-
emetics, antibiotics, antipyretics and blood products as 
necessary. However, the use of warfarin- type anticoagu-
lant therapies is not permitted.
treatment cycle assessments
Participants on the nal- IRI/5- FU/folinic acid treatment 
arm will have 2- weekly treatment cycles. Participants on 
the docetaxel treatment arm will have 3- weekly treatment 
cycles.
Assessments carried out on the first day of each treat-
ment cycle will include; laboratory assessments, clinical 
evaluation, vital signs, ECOG performance status, phys-
ical examination, details of concomitant medication and 
toxicity assessment (from cycle 2 onwards). Translational 
research blood samples and QoL questionnaires will be 
collected at 6- weekly intervals and at disease progression. 
A CT or MRI scan will be carried out 8 weekly (±7 days) 
from treatment start until disease progression or until 6 
months after the last participant is randomised, which-
ever occurs first. Disease progression will be defined as the 
date of the CT or MRI scan that identifies disease progres-
sion. In the rare circumstances that disease progression is 
determined clinically and it is not appropriate to confirm 
it radiologically, the date of progression will be defined as 
the date of documented clinical disease progression.
safety
Adverse events (AEs) and ARs will be collected on the 
first day of each treatment cycle from cycle 2 onwards. 
Serious AEs (SAEs), serious ARs (SARs) and suspected 
unexpected serious ARs (SUSARs) will be collected from 
registration. All AEs, ARs and SAEs will be collected until 
28 days after the last dose of trial treatment was adminis-
tered; SARs and SUSARs will be collected until the end 
of the study.
data collection
Data will be collected using paper case report forms and 
entered into a validated trial database by the CTRU, where 
data quality will be monitored. Automatic and manual 
validation of entered data will be conducted. Data items 
relating to the safety and rights of individual participants 
will be dealt with as a priority. Data items required for 
the primary endpoint analysis will be manually checked 
at the CTRU. Missing data will be chased until it is either 
received or confirmed as not available at the trial analysis 
stage.
statistical analysis
A full statistical analysis plan will be written before any 
analysis is undertaken.
The primary analysis population will be defined as 
those who have received at least one dose of the protocol 
treatment. Individuals will be analysed according to the 
treatment that they received rather than that which they 
M
edical Library. Protected by copyright.
 o
n
 February 18, 2020 at Assistant Librarian St Jam
es`s Hospital
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034527 on 5 February 2020. Downloaded from 
7Craig Z, et al. BMJ Open 2020;10:e034527. doi:10.1136/bmjopen-2019-034527
Open access
were randomised to receive. The QoL population is 
defined as any individual who returned at least one QoL 
questionnaire. Unless otherwise stated, the analysis will 
be conducted separately for each treatment group as per 
the primary analysis population.
All analyses will use a 5% significance level. The 
primary endpoint will be presented with a one- sided CI, 
while secondary endpoints will be presented with two- 
sided CIs. No formal interim analyses are scheduled to 
occur; hence, no statistical testing will take place until 
final analysis, which will occur once all randomised partic-
ipants have reached the primary endpoint. Nevertheless, 
the Data Monitoring and Ethics Committee (DMEC) will 
receive full reports, at least annually and safety reports 
at least 6- monthly, to monitor participant safety and trial 
progress, and they may prematurely terminate the trial if 
necessary.
Primary endpoint analysis of the proportion of partic-
ipants progression free at 6 months postrandomisation 
will be calculated using exact methods. If the one- sided CI 
for either treatment from this analysis includes 15%, then 
that treatment will not be considered for a phase III trial. 
An individual is defined to have achieved the primary 
endpoint if they do not progress within the time frame of 
treatment start date until 6 months postrandomisation. If 
an individual dies or is lost to follow- up, without confir-
mation of disease progression, within 6 months postran-
domisation, they will be considered to have not achieved 
this endpoint and will be censored at the date of death or 
date last known to be alive and progression free.
Secondary endpoint analysis will include summary 
statistics and Kaplan- Meier survival curves for PFS and 
OS, summaries of the number and cause of deaths, and 
calculation of the ORR (defined as the proportion of 
participants achieving at least a partial response within 
6 months postrandomisation).
Safety analyses will summarise AEs, ARs, SAEs, SARs, 
SUSARs and pregnancies. Line listings of SAEs will be 
generated and will include details on expectedness, 
causality, relationship to the trial treatment and outcome.
QoL will be summarised using mean scores for each 
subscale and repeated measures models will be employed 
to investigate changes in health- related QoL over time for 
each treatment group, using the QoL population.
In the event that both treatment groups meet the spec-
ified threshold for the primary endpoint, and show a 
similar level of efficacy, toxicity and QoL data will inform 
which treatment to investigate in further research.
Summary statistics for the concentration of neuron- 
specific enolase at each time point will be estimated. The 
baseline concentration of neuron- specific enolase will be 
analysed to assess whether it is associated with response to 
treatment at 6 months postrandomisation, via an ordinal 
logistic regression model, adjusting for the stratification 
factors (excluding hospital site) and any appropriate 
interaction variables.
Exploratory analysis of the primary and selected 
secondary endpoints (PFS, OS and ORR) will be done 
using logistic or Cox regression, as appropriate. All 
models will be adjusted for the stratification factors 
(excluding hospital site). Subgroup analysis of the 
primary and selected secondary endpoints (as above) 
will include investigation of gender, age, Ki-67 value and 
morphology of NEC. All exploratory and subgroup anal-
yses will be considered as hypothesis- generating rather 
than as confirmatory if significant differences are found. 
Further exploratory and subgroup analyses beyond that 
described may be undertaken.
trial monitoring
A trial monitoring plan will be developed by the trial 
management group (TMG) and agreed by the trial 
steering committee (TSC), based on the trial risk assess-
ment. The TMG, comprising the chief investigator, CTRU 
team, other key trial staff, a nursing representative and a 
patient and public involvement (PPI) representative will 
be assigned responsibility for the clinical setup, ongoing 
management, promotion of the trial and the interpreta-
tion and publishing of the results. The TSC and DMEC 
will provide independent oversight of the study and will 
be responsible for monitoring the study conduct. The 
TSC, comprising a statistician, an oncologist and a PPI 
representative will provide overall supervision of the 
trial. The DMEC, composed of two gastroenterologists, 
an oncologist (all with experience in the treatment of 
patients with NENs) and a statistician, will review the 
safety and ethics of the study alongside the trial progress, 
as overseen by the TSC. The DMEC will review confiden-
tial safety reports at least 6- monthly and the DMEC and 
TSC will meet separately, at least annually, to discuss trial 
progress.
Patient and public involvement
PPI representatives are involved in the design and overall 
direction of the trial through their roles in the TMG and 
the TSC. As part of the TMG, the PPI representative has 
been involved in protocol development and the prepa-
ration of the patient information and informed consent 
trial documentation. As part of the TSC, the PPI repre-
sentative will provide advice regarding trial design and 
conduct, and will be involved in monitoring trial progress 
and patient safety.
Ethics and dissemination
The NET-02 trial opened to recruitment on 16 November 
2018. At the time of submission, 12 centres out of 16 
are open to recruitment, and 17 participants have been 
randomised into the trial. The trial is currently adhering 
to V.3.0 of the protocol (approved 20 September 2018), 
with all sites opening to this version of the protocol. 
The trial is sponsored by The Christie NHS Foundation 
Trust, coordinated by Leeds CTRU and funded by Servier 
(unrestricted grant).
The trial will be conducted in accordance with Good 
Clinical Practice. Trial results will be published in peer- 
reviewed journals and will be reported in line with the 
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Consolidated Standards of Reporting Trials guidelines.31 
Authorship will be decided according to the International 
Committee of Medical Journal Editors criteria for author-
ship.32 All publications will be reviewed by the sponsor 
and funder prior to publication. To maintain the scientific 
integrity of the trial, data will not be released prior to the 
first publication of the analysis of the primary endpoint, 
for either trial publication or oral presentation purposes, 
without the permission of the sponsor and TSC. Research 
results will also be uploaded to the European Union Clin-
ical Trials Register.
All information collected during the course of the trial 
will be kept strictly confidential. Information will be held 
securely at the CTRU. The CTRU will comply with all 
aspects of the General Data Protection Regulation 2018.33 
The trial staff at the participating sites will be responsible 
for ensuring that any data or documentation sent to the 
CTRU is appropriately anonymised. At the end of the 
trial, data will be securely archived in line with the spon-
sor’s procedures for a minimum of 15 years. Data held by 
the CTRU will be archived in the sponsor archive facility, 
and site data and documents will be archived at the sites. 
Following authorisation from the sponsor, arrangements 
for confidential destruction will then be made.
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